Article
Oncology
Ji Young You, Eun Sook Lee, Siew Kuan Lim, Youngmee Kwon, So-Youn Jung
Summary: According to the study, performing sentinel lymph node biopsy (SLNB) without axillary lymph node dissection (ALND) may be a reasonable treatment option for patients with positive lymph nodes after breast cancer surgery. There was no significant difference in the loco-regional recurrence rates between SLNB with ALND and SLNB alone.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Peiyong Li, Ciqiu Yang, Junsheng Zhang, Yitian Chen, Xiaoqi Zhang, Minting Liang, Na Huang, Yilin Chen, Kun Wang
Summary: Sentinel lymph node biopsy can provide survival results equivalent to axillary lymph node dissection for patients with cN0 and T1-2 breast cancer; however, whether it can be performed on patients with T3-4c breast cancer is still controversial.
Article
Oncology
Ian Campbell, Neil Wetzig, Owen Ung, David Espinoza, Gelareh Farshid, John Collins, James Kollias, Val Gebski, Rebecca Mister, R. John Simes, Martin R. Stockler, Grantley Gill
Summary: For early breast cancer patients who are clinically node-negative, sentinel node-based management (SNBM) is the international standard of care. In the SNAC1 study, we report the rates of axillary recurrence, overall survival, and breast cancer-specific survival at 10 years.
Review
Oncology
Tzu-Wen Huang, Chih-Ming Su, Ka-Wai Tam
Summary: This study compared the real-world outcomes of SLNB alone and SLNB + ALND in early-stage breast cancer patients with limited positive SLN metastasis post-Z0011. It found that for patients with one or two SLN metastases, SLNB alone showed no significant difference in overall survival, disease-free survival, and recurrence rate compared to SLNB + ALND, and had a lower incidence of lymphedema.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Jing Si, Rong Guo, Huan Pan, Xiang Lu, Zhiqin Guo, Chao Han, Li Xue, Dan Xing, Wanxin Wu, Caiping Chen
Summary: The aim of this study was to determine whether breast cancer patients with mastectomy and false-negative frozen section in sentinel lymph node biopsy (SLNB) could forgo axillary lymph node dissection (ALND). The study found that SLNB and axillary radiation therapy could effectively replace ALND in selected patients who met specific criteria.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Gilles Houvenaeghel, Monique Cohen, Pedro Raro, Jeremy De Troyer, Pierre Gimbergues, Christine Tunon de Lara, Vivien Ceccato, Veronique Vaini-Cowen, Christelle Faure-Virelizier, Frederic Marchal, Tristan Gauthier, Eva Jouve, Pierrick Theret, Claudia Regis, Philippe Gabelle, Julia Pernaut, Francesco Del Piano, Gauthier D'Halluin, Stephane Lantheaume, Emile Darai, Bassoodeo Beedassy, Caroline Dhainaut-Speyer, Xavier Martin, Sophie Girard, Richard Villet, Emilie Monrigal, Theophile Hoyek, Jean-Francois Le Brun, Pierre-Emmanuel Colombo, Agnes Tallet, Jean-Marie Boher
Summary: The study analyzed the treatment and pathological results of patients included in the SERC trial, a multicenter randomized non-inferiority phase-3 trial comparing completion axillary lymph node dissection (cALND) with sentinel lymph node biopsy alone in breast cancer patients. Patients with one or two involved sentinel nodes by micro- or macro-metastases may not require cALND, but further research is needed for those with more than two involved nodes.
Article
Oncology
Anna C. Beck, Monica Morrow
Summary: Although sentinel lymph node biopsy is the preferred method for axillary staging and therapeutic for limited nodal disease, axillary lymph node dissection is still necessary in certain cases and for maintaining local control with heavy axillary tumor burden. Knowledge of the number of involved axillary nodes, obtained through axillary lymph node dissection, is also needed for tailored systemic therapies. Ongoing trials will explore the possibility of radiotherapy as a replacement for axillary lymph node dissection in certain circumstances.
Article
Oncology
Zhao Bi, Jia-Jian Chen, Peng-Chen Liu, Peng Chen, Wei-Li Wang, Yan-Bing Liu, Chun-Jian Wang, Peng-Fei Qiu, Qing Lv, Jiong Wu, Yong-Sheng Wang
Summary: This study developed a predictive model based on a multi-center retrospective database to accurately predict whether HR+/HER2- patients can undergo genomic tests. Through multivariate logistic regression analysis, imaging abnormal nodes, the number of positive SLNs, the number of negative SLNs, pathological tumor stage, and lympho-vascular invasion were identified as independent predictors for patients having <= 3 total metastatic ALNs.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jennifer Q. Zhang, Giacomo Montagna, Varadan Sevilimedu, Kelly Abbate, Jillian Charyn, Babak Mehrara, Monica Morrow, Andrea Barrio
Summary: This study evaluates the effect of axillary lymph node dissection (ALND) on quality of life (QOL) in breast cancer patients. The results show that QOL scores initially decrease after ALND but improve by 6 months post-surgery. Decreases in QOL were independent of arm volume. Patients with worse QOL were more likely to seek lymphedema therapy, although the effect of therapy on QOL remains unknown.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Surgery
Y. Andersson, L. Bergkvist, J. Frisell, J. de Boniface
Summary: The SENOMIC trial found that omitting axillary lymph node dissection in patients with breast cancer and sentinel node micrometastases had excellent 3-year event-free survival rates. However, patients who underwent mastectomy had worse tumor characteristics and higher risk of recurrence, especially without adjuvant radiotherapy. Long-term follow-up and enrollment of mastectomy patients are crucial.
BRITISH JOURNAL OF SURGERY
(2021)
Article
Oncology
Qiufan Zheng, Hanjia Luo, Wen Xia, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Fei Xu, Shusen Wang
Summary: This study found significant differences in overall survival and breast cancer-specific survival between SLNB and ALND, with SLNB showing a slight survival advantage.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Review
Surgery
Nur Amalina Che Bakri, Richard M. Kwasnicki, Naairah Khan, Omar Ghandour, Alice Lee, Yasmin Grant, Aleksander Dawidziuk, Ara Darzi, Hutan Ashrafian, Daniel R. Leff
Summary: This study evaluated the impact of axillary lymph node dissection (ALND) and sentinel lymph node biopsy (SLNB) on upper limb morbidity in breast cancer patients. The results showed that ALND patients had higher prevalence of lymphedema, pain, reduced strength, and range of motion compared with SLNB patients. These findings support the continued de-escalation of axillary surgery.
Article
Oncology
Matilda Appelgren, Helena Sackey, Yvonne Wengstrom, Karin Johansson, Johan Ahlgren, Yvette Andersson, Leif Bergkvist, Jan Frisell, Dan Lundstedt, Lisa Ryden, Malin Sund, Sara Alkner, Birgitte Vrou Offersen, Tove Filtenborg Tvedskov, Peer Christiansen, Jana de Boniface
Summary: This report evaluates the impact of axillary lymph node dissection (ALND) on health related quality of life (HRQoL) and patient-reported arm morbidity one year after breast cancer surgery. The study found that ALND did not have a negative impact on HRQoL and could reduce arm morbidity in patients.
Article
Oncology
Toralf Reimer
Summary: The local treatment of axilla in early breast cancer patients without clinically evident lymph node metastases is a subject of debate. Various prospective randomized surgical trials are currently being conducted to evaluate the safety of omitting sentinel lymph node biopsy in upfront breast-conserving surgery and neoadjuvant setting. These trials aim to determine whether it is possible to make therapeutic decisions without pathologic evaluation of nodal status. Additionally, ongoing trials are investigating the possibility of de-escalating surgery based on the response to neoadjuvant systemic therapy.
Article
Oncology
Maria Cristina Leonardi, Camilla Arrobbio, Sara Gandini, Stefania Volpe, Francesca Colombo, Eliana La Rocca, Viviana Galimberti, Sabrina Kahler-Ribeiro-Fontana, Cristiana Fodor, Samantha Dicuonzo, Damaris Patricia Rojas, Maria Alessia Zerella, Anna Morra, Emilia Montagna, Marco Colleoni, Giovanni Mazzarol, Laura Lavinia Travaini, Mattia Zaffaroni, Paolo Veronesi, Roberto Orecchia, Barbara Alicja Jereczek-Fossa
Summary: This study aimed to evaluate the rate of positive non-sentinel lymph nodes in breast cancer patients after neoadjuvant systemic therapy following positive sentinel lymph node biopsy. Positive non-SLNs were found in 62.3% of cases and were significantly associated with older age, clinically positive lymph nodes, SLN extracapsular extension, and a higher ratio of positive SLNs/total SLNs. ECE and higher nodal ratio were independent predictors of III axillary level positivity.
RADIOTHERAPY AND ONCOLOGY
(2021)
